Stereotaxis, Inc. (STXS) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory, primarily focusing on electrophysiology (cardiac ablation) using Robotic Magnetic Navigation (RMN). The company operates as a single segment. In July 2024, Stereotaxis acquired Access Point Technologies EP, Inc. ("APT"), adding in-house catheter manufacturing capabilities and the Map-iT product line.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $32.4 million | $26.9 million |
| Cost of Revenue | $15.3 million | $12.3 million |
| Gross Margin | $17.1 million (53%) | $14.6 million (54%) |
| Operating Loss | $(22.1 million) | $(24.7 million) |
| Net Loss | $(21.6 million) | $(24.0 million) |
| Cash and Cash Equivalents (Year End) | $13.4 million | $12.2 million |
| Working Capital | $11.5 million | $4.8 million |
| System Backlog (Year End) | $9.1 million | $14.4 million |
Debt and Liquidity: The company had no debt as of December 31, 2025. Liquidity is supported by cash on hand and recent equity financing, including a registered direct offering and an "at-the-market" (ATM) program.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 20% year-over-year, driven by an 18% increase in system sales and a 21% increase in disposables, service, and accessories revenue. The latter was bolstered by the full-year contribution from the APT acquisition.
- Operating Expenses: Operating expenses remained relatively flat at approximately $39.2 million. Research and Development (R&D) expenses decreased 4% due to the attainment of technological feasibility for the GenesisX system, offset by acquired headcount costs. General and Administrative (G&A) expenses increased 4%, primarily due to the revaluation of contingent consideration related to the APT acquisition.
- Backlog Decline: System backlog decreased from $14.4 million in 2024 to $9.1 million in 2025. Management expects approximately 78% of the 2025 backlog to be recognized as revenue in 2026.
- Stock-Based Compensation: Significant stock-based compensation expense was recorded for the CEO Performance Award ($7.1 million in 2025), which is recognized regardless of milestone achievement.
Guidance, Outlook, and Risks
Outlook and Commentary: Management expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The company anticipates periodic disruptions to manufacturing and supply chains due to macroeconomic factors. The company believes its cash position is sufficient to meet obligations for at least 12 months following the report date.
Key Risks and Contingencies:
- Supply Chain & Strategic Relationships: The obligation of Johnson & Johnson (J&J) to supply compatible ablation catheters ended on December 31, 2025. While Stereotaxis is ramping up production of its proprietary MAGiC catheter (FDA clearance expected early 2026), there is no guarantee that J&J will continue supply into 2026, which could impact revenue.
- Liquidity: The company has an accumulated deficit of $583.4 million and may require additional capital to fund operations and growth.
- Regulatory: Continued reliance on FDA and international regulatory approvals for new devices (e.g., MAGiC, EMAGIN) and the maintenance of existing clearances.
- CEO Compensation: The 2021 CEO Performance Award creates significant non-cash expense and potential dilution (up to 13 million shares) if market capitalization milestones are met.
Investor Verification Checklist
- Catheter Supply Transition: Verify the status of the transition from J&J catheters to the proprietary MAGiC catheter and confirm the timeline for FDA clearance in early 2026.
- Backlog Conversion: Monitor the conversion rate of the $9.1 million system backlog into recognized revenue in 2026, noting the risk of order cancellations or delays.
- Liquidity Runway: Assess the sufficiency of the $13.4 million cash balance against the projected operating burn rate and the potential need for further equity dilution.
- APT Integration: Review the financial performance of the APT acquisition and the achievement of revenue milestones triggering contingent earnout payments.
- CEO Performance Award: Track the market capitalization milestones required for the CEO Performance Award vesting and the associated impact on stock-based compensation expenses.